VIR vs ANNX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VIR Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vir Biotechnology, Inc. Common Stock (VIR) driven by superior Valuation, Momentum & Technical while ANNX counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, VIR trades at 4.3x Forward P/E with -70.2% operating margin (+19582.5% YoY revenue) versus ANNX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VIR sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro) against ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIR | ANNX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $747.8M | Larger Scale | VIR |
| Trailing P/E Ratio Valuation | 4.3x | N/M | Lower Multiple | VIR |
| Forward P/E Ratio Valuation | 4.3x | N/M | Lower Multiple | VIR |
| Revenue Growth (YoY) Growth | +19582.5% | +0.0% | Higher Growth | VIR |
| Operating Margin (TTM) Profitability | -70.2% | 0.0% | Higher Margin | ANNX |
| Net Profit Margin Profitability | -61.0% | 0.0% | Higher Margin | ANNX |
| Return on Equity (ROE) Capital Efficiency | -21.8% | -130.8% | Higher ROE | VIR |
| 52-Week Range Position Momentum | 43% ($5โ$14) | 18% ($3โ$7) | Stronger Trend | VIR |
| Beta / 30D Volatility Risk Regime | 1.75ฮฒ ยท 101% Vol | 1.70ฮฒ ยท 63% Vol | Lower Realized Risk | ANNX |
| Unified Institutional Score Composite Signal | 46.2 / 100 (HOLD) | 43.5 / 100 (HOLD) | Higher Composite | VIR |